Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

CRISPR-Editing Therapy for Duchenne Muscular Dystrophy

Human Gene Therapy(2023)10.1089/hum.2023.053Source: DataRank Database

CRISPR-Editing Therapy for Duchenne Muscular Dystrophy is a research paper published in Human Gene Therapy (2023). On theSindex it has a DataRank of 1.1. It has been cited 41 times, with 38 citing works in its 1-hop citation network.

N/A

1.1DataRank · unranked

Scored on demand from live citation data

41 citations · 38 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 3.80)OA: greenTopics (43)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 53%Citation Network 47%

Base Score Contribution

0.561

From this paper's citation signal

Citation Network Contribution

0.495

From 29 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 38 citers.

Duchenne Muscular Dystrophy Gene Therapy in 2023: Status, Perspective, and Beyond
Human Gene Therapy202335 citations47 referencesContributes 0.076
De Novo p.Asp3368Gly Variant of Dystrophin Gene Associated with X-Linked Dilated Cardiomyopathy and Skeletal Myopathy: Clinical Features and In Silico Analysis
International Journal of Molecular Sciences20246 citations30 referencesContributes 0.065
Gene therapy for Duchenne muscular dystrophy
Brain and Development20259 citations45 referencesContributes 0.051
Dual pH-responsive CRISPR/Cas9 ribonucleoprotein xenopeptide complexes for genome editing
European Journal of Pharmaceutical Sciences20249 citations60 referencesContributes 0.038
Gene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments
Expert Review of Neurotherapeutics202324 citations88 referencesContributes 0.037

Authors (3)

Eric N. Olson ORCID,Rhonda Bassel‐Duby ORCID,Francesco Chemello ORCID

Live enrichment

PubMed:37060194 OpenAlex:https://openalex.org/W4365811064

NICHD NIH HHS

Grant: P50 HD087351

NHLBI NIH HHS

Grant: R01 HL130253

NHLBI NIH HHS

Grant: R01 HL157281

FWCI

3.80

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

greenLicense: https://journals.sagepub.com/page/policies/text-and-data-mining-license

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10210224/pdf/hum.2023.053.pdf

publisherhttps://journals.sagepub.com/doi/full-xml/10.1089/hum.2023.053

publisherhttps://journals.sagepub.com/doi/pdf/10.1089/hum.2023.053

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10210224

Fields of Study

CRISPR and Genetic EngineeringVirus-based gene therapy researchMuscle Physiology and DisordersMiceHumansAnimalsMuscular Dystrophy, DuchenneCRISPR-Cas SystemsGenetic TherapyExonsDystrophinGene EditingDisease Models, Animal

MeSH Terms

Gene EditingAnimalsDisease Models, AnimalExonsHumansGenetic TherapyDystrophinMuscular Dystrophy, DuchenneMiceCRISPR-Cas Systems

Keywords

Genome editingCRISPRDuchenne muscular dystrophyGenetic enhancementCas9DystrophinMuscular dystrophyTranscription activator-like effector nucleaseBiologyGeneMuscle disorderZinc finger nucleaseComputational biologyMutationGeneticsBioinformaticsMedicineAAV vectorsCRISPR-Cas9gene editing

Sustainable Development Goals

SDG 0: Good health and well-being